McLaughlin, Peter <br/><br/>
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha.  [electronic resource] 

 -  Blood  Jun 2005 
 - 4573-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0006-4971 
<br/><br/><label>Standard No.: </label>10.1182/blood-2004-08-3035  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Chromosome Aberrations<br/>Chromosomes, Human, Pair 7<br/>Combined Modality Therapy<br/>DNA Damage<br/>Dexamethasone--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Immunotherapy--methods<br/>Interferon-alpha--administration & dosage<br/>Leukemia, Myeloid, Acute--chemically induced<br/>Lymphoma--drug therapy<br/>Male<br/>Middle Aged<br/>Mitoxantrone--administration & dosage<br/>Monosomy<br/>Myelodysplastic Syndromes--chemically induced<br/>Remission Induction<br/>Rituximab<br/>Time Factors<br/>Vidarabine--administration & dosage